Adaptive Biotechnologies Corp (ADPT)
9.32
+0.17
(+1.86%)
USD |
NASDAQ |
May 29, 14:36
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.416B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 150.7% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.276 |
| Price to Book Value | 7.435 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.55% |
Profile
Edit
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |
| URL | https://www.adaptivebiotech.com |
| Investor Relations URL | https://investors.adaptivebiotech.com/ |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Aug. 01, 2025 (est.) |
| Last Earnings Release | May. 01, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |
| URL | https://www.adaptivebiotech.com |
| Investor Relations URL | https://investors.adaptivebiotech.com/ |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Aug. 01, 2025 (est.) |
| Last Earnings Release | May. 01, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |